Sangamo Therapeutics, Inc (SGMO) — 10-Q Filings
All 10-Q filings from Sangamo Therapeutics, Inc. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (5)
-
Sangamo's Revenue Plunges 98% Amid Mounting Losses, Going Concern Doubts
— Nov 6, 2025 Risk: high
SANGAMO THERAPEUTICS, INC. (SGMO) reported a significant decline in revenue and a substantial net loss for the three and nine months ended September 30, 2025. R -
Sangamo's Q2 Loss Widens to $75.2M Amid Revenue Decline
— Aug 7, 2025 Risk: high
Sangamo Therapeutics, Inc. reported a net loss of $75.2 million for the three months ended June 30, 2025, a significant increase from the $60.5 million net loss -
Sangamo Therapeutics Files Q1 2025 10-Q Report
— May 12, 2025 Risk: medium
Sangamo Therapeutics, Inc. filed its quarterly report for the period ending March 31, 2025. The company's financial statements and disclosures are presented in -
Sangamo Therapeutics Files Q3 2024 10-Q
— Nov 12, 2024 Risk: medium
Sangamo Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Sangamo Biosciences Inc., is a biotechnology -
Sangamo Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024
— May 9, 2024 Risk: medium
SANGAMO THERAPEUTICS, INC (SGMO) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Sangamo Therapeutics, Inc. filed a 10-Q report for the period endi
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX